On the 19th, Foresee Pharmaceuticals announced that its new formulation of CAMCEVI (leuprolide injectable emulsion) for prostate cancer has been accepted for substantive review by China’s National Medical Products Administration (NMPA). Based on standard review timelines, the approval process is expected to take approximately 18 to 24 months, with the earliest possible approval anticipated in the second half of 2025.
Read more
